Viatris Return on Tangible Equity 2010-2025 | VTRS

Current and historical return on tangible equity values for Viatris (VTRS) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Viatris Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2025-03-31 $-3.79B $-7.47B 48.88%
2024-12-31 $-0.63B $-7.57B 7.84%
2024-09-30 $-0.88B $-7.75B 10.59%
2024-06-30 $-0.65B $-8.23B 7.12%
2024-03-31 $-0.06B $-8.81B 0.56%
2023-12-31 $0.05B $-8.58B -0.51%
2023-09-30 $1.83B $-10.69B -15.67%
2023-06-30 $1.85B $-11.77B -14.84%
2023-03-31 $1.90B $-12.35B -14.37%
2022-12-31 $2.08B $-11.96B -14.72%
2022-09-30 $0.80B $-13.89B -5.16%
2022-06-30 $0.76B $-14.82B -4.59%
2022-03-31 $0.17B $-15.78B -0.96%
2021-12-31 $-1.27B $-17.76B 6.92%
2021-09-30 $-1.92B $-18.02B 10.28%
2021-06-30 $-2.05B $-18.65B 12.61%
2021-03-31 $-1.73B $-18.98B 12.57%
2020-12-31 $-0.67B $-19.08B 5.94%
2020-09-30 $0.27B $-8.24B -3.01%
2020-06-30 $0.27B $-8.73B -2.93%
2020-03-31 $0.06B $-9.11B -0.65%
2019-12-31 $0.02B $-9.36B -0.17%
2019-09-30 $0.05B $-9.75B -0.45%
2019-06-30 $0.03B $-10.52B -0.31%
2019-03-31 $0.24B $-10.67B -2.11%
2018-12-31 $0.35B $-11.25B -2.99%
2018-09-30 $0.55B $-11.97B -4.54%
2018-06-30 $0.46B $-11.83B -3.80%
2018-03-31 $0.72B $-12.19B -5.91%
2017-12-31 $0.70B $-12.14B -5.75%
2017-09-30 $0.87B $-11.96B -7.12%
2017-06-30 $0.66B $-12.17B -5.26%
2017-03-31 $0.53B $-12.11B -5.15%
2016-12-31 $0.48B $-12.56B -6.04%
2016-09-30 $0.26B $-13.42B -4.66%
2016-06-30 $0.81B $-3.22B -29.80%
2016-03-31 $0.81B $-2.57B -32.00%
2015-12-31 $0.85B $-2.84B -32.98%
2015-09-30 $0.84B $-2.20B -31.87%
2015-06-30 $0.91B $-2.47B -31.20%
2015-03-31 $0.87B $-2.79B -27.42%
2014-12-31 $0.93B $-3.12B -27.47%
2014-09-30 $0.92B $-3.32B -25.72%
2014-06-30 $0.58B $-3.46B -17.71%
2014-03-31 $0.63B $-3.63B -21.04%
2013-12-31 $0.62B $-3.90B -22.54%
2013-09-30 $0.61B $-2.12B -25.36%
2013-06-30 $0.66B $-2.39B -27.03%
2013-03-31 $0.62B $-2.67B -24.48%
2012-12-31 $0.64B $-2.38B -26.03%
2012-09-30 $0.61B $-2.30B -24.05%
2012-06-30 $0.55B $-2.76B -21.93%
2012-03-31 $0.56B $-2.41B -23.22%
2011-12-31 $0.54B $-2.64B -22.54%
2011-09-30 $0.41B $-2.29B -17.54%
2011-06-30 $0.36B $-2.32B -14.97%
2011-03-31 $0.27B $-2.25B -11.07%
2010-12-31 $0.22B $-2.49B -9.14%
2010-09-30 $0.22B $-2.59B -9.11%
2010-06-30 $0.08B $-2.28B -3.05%
2010-03-31 $0.08B $-2.40B -3.20%
2009-12-31 $0.09B $-2.57B -3.50%
Sector Industry Market Cap Revenue
Medical Medical Services $10.610B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $145.009B 27.20
Elevance Health (ELV) United States $86.741B 11.19
CVS Health (CVS) United States $81.290B 10.10
Cencora (COR) United States $55.092B 19.17
DiDi Global (DIDIY) China $23.485B 35.64
Natera (NTRA) United States $22.560B 0.00
BioMerieux (BMXMF) France $16.856B 0.00
Solventum (SOLV) United States $13.071B 13.84
EUROFINS SCIENT (ERFSF) Luxembourg $13.026B 0.00
ICON (ICLR) Ireland $11.688B 10.87
Revvity (RVTY) United States $11.345B 19.52
CochLear (CHEOY) Australia $11.134B 0.00
Doximity (DOCS) United States $10.995B 50.90
Avantor (AVTR) United States $9.329B 13.55
HealthEquity (HQY) United States $9.272B 40.61
Medpace Holdings (MEDP) United States $8.792B 23.35
Sonic Healthcare (SKHHY) Australia $8.450B 0.00
Charles River Laboratories (CRL) United States $7.416B 14.53
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.450B 26.21
BrightSpring Health Services (BTSG) United States $3.875B 35.87
Sotera Health (SHC) United States $3.491B 19.84
Surgery Partners (SGRY) United States $2.989B 38.87
Alignment Healthcare (ALHC) United States $2.898B 0.00
Concentras Parent (CON) United States $2.816B 16.27
Organon (OGN) United States $2.610B 2.77
GeneDx Holdings (WGS) United States $1.983B 76.39
Progyny (PGNY) United States $1.923B 42.32
Ardent Health Partners (ARDT) United States $1.920B 8.18
Premier (PINC) United States $1.884B 14.30
PACS (PACS) United States $1.629B 0.00
GoodRx Holdings (GDRX) United States $1.622B 32.43
Teladoc Health (TDOC) United States $1.298B 0.00
Pediatrix Medical (MD) United States $1.213B 9.23
Establishment Labs Holdings (ESTA) $1.124B 0.00
CareDx (CDNA) United States $1.105B 17.26
Ryman Healthcare (RYHTY) New Zealand $1.011B 0.00
Agilon Health (AGL) United States $0.944B 0.00
AMN Healthcare Services Inc (AMN) United States $0.843B 7.89
QDM (QDMI) Hong Kong, SAR China $0.752B 0.00
Nutex Health (NUTX) United States $0.651B 9.85
Embecta (EMBC) United States $0.592B 3.99
LifeMD (LFMD) United States $0.553B 0.00
Enhabit (EHAB) United States $0.543B 44.67
InnovAge Holding (INNV) United States $0.514B 0.00
SBC Medicals (SBC) United States $0.495B 0.00
Sonida Senior Living (SNDA) United States $0.474B 0.00
Auna S.A (AUNA) Luxembourg $0.470B 10.58
COMPASS Pathways (CMPS) United Kingdom $0.445B 0.00
Performant Healthcare (PHLT) United States $0.258B 0.00
Oncology Institute (TOI) United States $0.237B 0.00
Beauty Health (SKIN) United States $0.202B 0.00
DocGo (DCGO) United States $0.156B 25.50
KindlyMD (KDLY) United States $0.150B 0.00
Pheton Holdings (PTHL) China $0.104B 0.00
So-Young (SY) China $0.090B 0.00
OncoCyte (OCX) United States $0.079B 0.00
Basel Medical Group (BMGL) Singapore $0.075B 0.00
KindlyMD (NAKA) United States $0.070B 0.00
Ascend Wellness Holdings (AAWH) United States $0.060B 0.00
NeueHealth (NEUE) United States $0.060B 0.00
IceCure Medical (ICCM) Israel $0.057B 0.00
Sera Prognostics (SERA) United States $0.056B 0.00
Biodesix (BDSX) United States $0.048B 0.00
ModivCare (MODV) United States $0.047B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.029B 0.00
SeaStar Medical Holding (ICU) United States $0.013B 0.00
Intelligent Bio Solutions (INBS) United States $0.013B 0.00
Co-Diagnostics (CODX) United States $0.010B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
INVO Fertility (IVF) United States $0.003B 0.00
NewGenIvf Group (NIVF) Thailand $0.001B 0.00
Cano Health (CANOQ) United States $0.000B 0.00